Feb 27 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
* Regulators investigating alleged interest-rate manipulation are hoping to reach settlements with at least three major financial institutions by the end of summer, according to a person familiar with the probes.
* JPMorgan Chase & Co stepped up the pace of bank cost cutting, setting plans to eliminate 17,000 jobs by the end of next year and reduce expenses by at least $1 billion annually.
* U.S. Federal Reserve Chairman Ben Bernanke came down firmly in favor of continuing the central bank’s bond-buying programs, even as he acknowledged concerns that the efforts might encourage risk-taking that could someday destabilize markets or the economy.
* Pay-TV distributor Cablevision Systems Corp sued MTV’s owner Viacom Inc alleging antitrust violations. Cablevision alleged Viacom forced it to carry and pay for more than a dozen “lesser-watched” channels such as “Palladia, MTV Hits and VH1 Classic” for the right to carry its popular networks such as Nickelodeon, MTV and Comedy Central.
* Boeing Co’s proposed fixes for lithium-ion batteries on its 787 jetliner face an uncomfortable reality: government investigators’ limited experience with such devices is hobbling efforts to determine precisely why they burned.
* Wall Street cash bonuses for 2012 are expected to climb 8 percent to $20 billion from a year earlier, boosted in part by the payment this year of compensation deferred from prior years, according to a report from New York State Comptroller Thomas DiNapoli.
* Clearwire Corp plans to tap financing made available by Sprint Nextel Corp, people familiar with the situation said, in a move that further complicates Dish Network Corp’s effort to buy the wireless broadband operator.
* New Jersey Governor Chris Christie signed a bill that legalizes online gambling in the state, allowing Atlantic City casino companies to take bets online.
* Much anticipated knockoff versions of costly biotech medicines are facing delays and obstacles that could cost patients and health systems billions in missed savings - several high-profile projects have faltered in recent months.